From: Differences in discontinuation of statin treatment in women and men with advanced cancer disease
Total (N = 54) | Men (N = 25) | Women (N = 29) | p | |
---|---|---|---|---|
Patients’ characteristics | ||||
Age (years) | 72 ± 10 | 71 ± 11 | 73 ± 8 | ns |
Age > 75 years, n (%) | 20 | 10 | 10 | ns |
Albumin (g/L) | 27 ± 7 | 27 ± 6 | 27 ± 7 | ns |
CRP (mg/L) | 65 ± 27 | 63 ± 126 | 66 ± 82 | ns |
25-OHD (nmol/L) | 45 ± 29 | 43 ± 26 | 47 ± 32 | ns |
ESAS QoL | 5.7 ± 2.5 | 6.5 ± 2.4 | 5.0 ± 2.4 | 0.03 |
History of stroke, n | 6 | 4 | 2 | ns |
History of myocardial infarction, n | 12 | 8 | 4 | ns |
Survival time (months) | 3.3 ± 4.5 | 2.2 ± 2.5 | 4.3 ± 5.5 | ns (0.10) |
Highest educational level | ||||
University degree | 4 | 2 | 2 | ns |
No university degree | 30 | 14 | 16 | ns |
Unknown | 20 | 9 | 11 | ns |
Indication for statin use | ||||
Primary prevention, n | 36 | 13 | 23 | |
Secondary prevention, n | 18 | 12 | 6 | 0.03 |
Type of statin, n mean dose (mg) | ||||
Simvastatin | 41 28 mg | 21 31 mg | 20 24 mg | ns |
Atorvastatin | 10 23 mg | 3 27 mg | 7 19 mg | ns |
Rosuvastatin | 2 10 mg | 0 | 2 10 mg | ns |
Pravastatin | 1 20 mg | 1 20 mg | 0 | ns |